Aquestive Therapeutics, Inc. (AQST)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Daniel Barber | CEO, President & Director | 1.1M | -- | 1976 |
| Mr. Alexander Mark Schobel | Chief Innovation & Technology Officer | 2.6M | -- | 1959 |
| Ms. Lori J. Braender BSBA, Esq., J.D. | Chief Legal Officer, Chief Compliance Officer & Secretary | 737.77k | -- | 1956 |
| Mr. A. Ernest Toth Jr. | Chief Financial Officer | 667.19k | -- | 1959 |
| Ms. Cassie Jung | Chief Operating Officer | -- | -- | 1980 |
| Ms. Sherry Korczynski | Senior Vice President of Sales & Marketing | -- | -- | 1970 |
| Mr. Peter E. Boyd | Senior Vice President of Information Technology & Human Resources | -- | -- | 1966 |
| Dr. Gary H. Slatko M.D., MBA | Chief Medical Officer | -- | -- | 1957 |
| Dr. Carl N. Kraus M.D. | Chief Medical Officer | -- | -- | 1970 |
| Dr. Melina T. Cioffi | Senior Vice President of Regulatory Affairs | -- | -- | 1983 |
Aquestive Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 142
Description
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Corporate Governance
Upcoming Events
August 4, 2025 at 10:59 AM UTC - August 8, 2025 at 12:00 PM UTC
Aquestive Therapeutics, Inc. Earnings Date